艾曲波帕联合用药治疗成人原发免疫性血小板减少症的有效性及安全性系统评价

曹新甜; 胡晓梅; 孙妍; 宋英; 吕妍; 肖海燕; 全日城

doi:10.13201/j.issn.1004-2806.2021.07.009

艾曲波帕联合用药治疗成人原发免疫性血小板减少症的有效性及安全性系统评价

- 1. 北京中医药大学附属西苑医院临床学院(北京, 100029);
- 2. 中国中医科学院西苑医院
基金项目:
国家重点基础研究发展计划(973计划)(No:2015CB554403)

详细信息

通讯作者: 全日城,E-mail:quanrc@126.com

中图分类号: R558.2

收稿日期: 2021-01-23

Effect and safety of eltrombopag combined with other drugs treatment for adult primary immune thrombocytopenia:A systematic review

- 1. Xiyuan Clinical Medical College, Beijing University of Chinese Medicine, Beijing, 100029, China;
- 2. Xiyuan Hospital, China Academy of Chinese Medical Sciences

More Information

Corresponding author: QUAN Richeng, E-mail: quanrc@126.com

Received Date: 23 January 2021

摘要

摘要: 目的:系统评价艾曲波帕联合用药治疗成人原发免疫性血小板减少症(ITP)的有效性与安全性。方法:检索Medline,PubMed,Cochrane图书馆、Embase、知网期刊数据库、万方数据库,纳入以艾曲波帕联合其他药物为干预措施治疗成人ITP的文献,检索时间从建库至2020年12月,利用SPSS 25.0软件进行数据分析。结果:共纳入8篇文献,286例患者。1篇文献报道了艾曲波帕联合利妥昔单抗的有效率显著高于单用艾曲波帕(75.0%vs 41.7%,P<0.05)。2篇文献报道了艾曲波帕联合重组人血小板生成素(rhTPO)的有效率显著高于单用rhTPO(94.4%vs 75.0%,P<0.05;78.1%vs 56.3%,P<0.05)。1篇文献报道了艾曲波帕联合地塞米松的有效率显著高于单用地塞米松(94.4%vs 81.5%,P<0.05)。上述4篇文献艾曲波帕联合用药与单药比较,不良事件发生率差异均无统计学意义(P>0.05)。2篇文献报道了艾曲波帕联合地塞米松的方案,但无对照组,有效率分别为97.8%、100%,其中1篇不良事件发生率为51.1%。1篇文献报道了艾曲波帕联合地塞米松及利妥昔单抗的三联方案,但无对照组,有效率为100%,不良事件发生率为30.8%。1篇文献报道了艾曲波帕联合硫唑嘌呤的有效率与环孢素联合达那唑比较,差异无统计学意义(69.6%vs 73.9%,P>0.05),但前者不良事件发生率显著低于后者(34.8%vs 69.6%,P<0.05)。进一步比较分析显示,艾曲波帕联合地塞米松有效率(97.3%)显著高于艾曲波帕联合硫唑嘌呤(69.9%)(P<0.001)、艾曲波帕联合利妥昔单抗(75.0%)(P=0.008)、艾曲波帕联合rhTPO(84.0%)(P=0.006),但艾曲波帕联合rhTPO的不良事件发生率(16.0%)显著低于艾曲波帕联合地塞米松(52.4%)(P<0.001)。结论:与单药相比较,艾曲波帕联合用药的有效性显著提高,安全性没有差异。艾曲波帕联合地塞米松有效率显著高于联合硫唑嘌呤、利妥昔单抗以及rhTPO,但安全性不及艾曲波帕联合rhTPO。
- 原发免疫性血小板减少症 /
- 艾曲波帕 /
- 联合用药 /
- 有效性 /
- 安全性
Abstract: Objective: To evaluate the efficacy and safety of eltrombopag combined with other drugs for the treatment of primary immune thrombocytopenia(ITP).Methods: Medline, Pubmed, Cochrane Library, Embase, CNKI and Wanfang database were searched until December 2020 about studies of eltrombopag combined with other drugs on the treatment of ITP disease. Statistical analysis was performed with SPSS software version 25.0.Results: Eight studies involving 286 patients were included. One study showed that response rate of eltrombopag+rituximab was significantly higher than that of eltrombopag(75.0% vs 41.7%, P<0.05). Two studies showed that response rates of eltrombopag+recombinant human thrombopoietin(rhTPO) were significantly higher than those of rhTPO(94.4% vs 75.0%, P<0.05, 78.1% vs 56.3%, P<0.05). One study showed that response rate of eltrombopag+dexamethasone was significantly higher than that of dexamethasone(94.4% vs 81.5%, P<0.05). Four studies above-mentioned showed that adverse event rates of eltrombopag combined with other drugs had no significant difference compared with single drug(P>0.05).Two studies with no control group showed that response rates of eltrombopag+dexamethasone were 97.8% and 100% respectively, and one study showed that adverse event rate of eltrombopag+dexamethasone was 51.1%. One study showed trigeminy regimen of eltrombopag+dexamethasone+rituximab, the response rate was 100% and adverse event rate was 30.8%. One study showed that response rates of eltrombopag+azathioprine and cyclosporine+dazol were 69.6% and 73.9% respectively, with no significant difference(P>0.05), but adverse event rate of the former was lower than the latter(34.8% vs 69.6%, P<0.05). Further analysis showed significant differences among the regimen of eltrombopag combined with other drugs. The response rate of eltrombopag+dexamethasone(97.3%) was significantly higher than eltrombopag+azathioprine(69.9%)(P<0.001), eltrombopag+rituximab(75.0%)(P=0.008), eltrombopag+rhTPO(84.0%)(P=0.006). The adverse event rate of eltrombopag+rhTPO(16.0%) was significantly lower than that of eltrombopag+dexamethasone(52.4%)(P<0.001).Conclusion: Compared with single drug, the response rates of eltrombopag combined with other drugs are significantly higher, the adverse event rates have no significant difference. The response rate of eltrombopag+dexamethasone is significantly higher than that of eltrombopag+rituximab, eltrombopag+rhTPO, but the adverse event rate is significantly higher than that of eltrombopag+rhTPO.
- primary immune thrombocytopenia /
- eltrombopag /
- drug combition /
- efficacy /
- safety

HTML全文

参考文献(36)

[1]	Onisâi M,Vlǎdǎreanu AM,Spînu A,et al.Thrombocytopenic purpura(ITP)-new era for an old disease[J].Rom J Intern Med,2019,57(4):273-283.
[2]	张之南.血液病学[M].2版.北京:人民卫生出版社,2011:1273-1274.
[3]	中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2020年版)[J].中华血液学杂志,2020,41(8):617-623.
[4]	李召,刘璐,杜雅慧,等.利妥昔单抗联合艾曲波帕治疗难治性原发免疫性血小板减少症一例[J].中华内科杂志,2017,56(1):52-54.
[5]	Kuter DJ.The biology of thrombopoietin and thrombopoietin receptor agonists[J].Int J Hematol,2013,98(1):10-23.
[6]	孙慧平,范青叶,游建华,等.艾曲泊帕长期治疗成人慢性免疫性血小板减少症的疗效和安全性[J].临床血液学杂志,2020,33(1):39-43.
[7]	侯明,刘新光.立足中国实际的原发免疫性血小板减少症诊治——2020版成人原发免疫性血小板减少症诊断与治疗中国指南解读[J].临床血液学杂志,2021,34(1):1-4.
[8]	Rodeghiero F,Stasi R,Gernsheimer T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood,2009,113(11):2386-2393.
[9]	白浩成,冯静,袁忠涛,等.小剂量利妥昔单抗联合艾曲波帕治疗激素耐药性ITP的临床疗效[J].西部医学,2020,32(1):121-124.
[10]	顾小慧,赵凤晓,尹淑荣.艾曲波帕联合重组人血小板生成素治疗难治性血小板减少性紫癜的疗效分析[J].中外医疗,2020,39(2):101-103.
[11]	李蒲,胡锦芳.艾曲波帕乙醇胺片联合重组人血小板生成素注射液治疗血小板减少症患者的临床研究[J].中国临床药理学杂志,2020,36(7):750-752.
[12]	洪攀,傅佳萍,封蔚莹,等.艾曲波帕联合大剂量地塞米松治疗ITP疗效分析[J].浙江临床医学,2020,22(7):1025-1027.
[13]	Gómez-Almaguer D,Herrera-Rojas MA,Jaime-Pérez JC,et al.Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults[J].Blood,2014,123(25):3906-3908.
[14]	Zhang L,Zhang M,Du X,et al.Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia[J].Br J Haematol,2020,189(2):369-378.
[15]	Gómez-Almaguer D,Colunga-Pedraza PR,Gómez-De León A,et al.Eltrombopag,low-dose rituximab,and dexamethasone combition as frontline treatment of newly diagnosed immune thrombocytopaenia[J].Br J Haematol,2019,184(2):288-290.
[16]	罗洪强,钟永根,封蔚莹.艾曲波帕联合硫唑嘌呤治疗难治性特发性血小板减少性紫癜的疗效及其对细胞免疫功能的影响研究[J].中国全科医学,2019,22(21):2588-2592.
[17]	刘伯轩.大剂量地塞米松对免疫性血小板减少症患者CD4+ CD25+调节性T淋巴细胞水平的影响研究[J].临床研究,2020,28(10):116-117.
[18]	闫志凌,李振宇,张焕新,等.大剂量地塞米松联合小剂量利妥昔单抗作为二线方案治疗65例原发免疫性血小板减少症患者的临床观察[J].中华血液学杂志,2015,36(3):206-209.
[19]	侯明.免疫性血小板减少症的治疗进展[J].临床血液学杂志,2020,33(1):6-9.
[20]	Wang S,Yang R,Zou P,et al.A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J].Int J Hematol,2012,96(2):222-228.
[21]	Zhou H,Xu M,Qin P,et al.A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP[J].Blood,2015,125(10):1541-1547.
[22]	Vadhan-Raj S.Recombint human thrombopoietin in myelosuppressive chemotherapy[J].Oncology,2001,15(7 Suppl 8):35-38.
[23]	刘一,吕欣,董振香.重组人血小板生成素的药理作用和临床评价[J].中国新药杂志,2008,17(3):254-258.
[24]	高然,曲艺,李艳.重组人血小板生成素治疗难治性特发性血小板减少性紫癜的临床观察[J].山西医药杂志,2012,41(7):724-726.
[25]	吴秋玲,何静,陈燕,等.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的临床研究[J].华中科技大学学报(医学版),2004,33(3):297-299.
[26]	Stasi R.Rituximab in autoimmune hematologic diseases:not just a matter of B cells[J].Semin Hematol,2010,47(2):170-179.
[27]	李燕青,郭春连,卢家淇.小剂量利妥昔单抗治疗复发难治性原发免疫性血小板减少症的临床疗效观察[J].吉林医学,2019,40(12):2828-2829.
[28]	裴丽,罗艳,李翔.硫唑嘌呤不良反应的临床表现与安全用药[J].实用药物与临床,2013,16(9):845-848.
[29]	Liang Y,Song MM,Liu SY,et al.Relationship between expression of glucocorticoid receptor isoforms and glucocorticoid resistance in immune thrombocytopenia[J].Hematology,2016,21(7):440-446.
[30]	蒋亘乔,魏昱,曹晶晶,等.免疫性血小板减少症的激素耐药与P-糖蛋白表达和功能活性的相关性[J].内科理论与实践,2020,15(5):341-346.
[31]	González-López TJ,Fernández-Fuertes F,Hernández-Rivas JA,et al.Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice[J].Int J Hematol,2017,106(4):508-516.
[32]	Fattizzo B,Levati G,Cassin R,et al.Eltrombopag in Immune Thrombocytopenia,Aplastic Anemia,and Myelodysplastic Syndrome:From Megakaryopoiesis to Immunomodulation[J].Drugs,2019,79(12):1305-1319.
[33]	Steurer M,Quittet P,Papadaki HA,et al.A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice[J].Eur J Haematol,2017,98(2):112-120.
[34]	Gonzalez-Porras JR,Mingot-Castellano ME,Andrade MM,et al.Use of eltrombopag after romiplostim in primary immune thrombocytopenria[J].Br J Haematol,2015,169(1):111-126.
[35]	George JN,Mathias SD,Go RS,et al.Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura:results from two randomized,placebo-controlled trials[J].Br J Haematol,2009,144(3):409-415.
[36]	Bussel JB,Cheng G,Saleh MN,et al.Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J].N Engl J Med,2007,357(22):2237-2247.